SCHEMBL26506581

SCHEMBL26506581

COC(=O)c1ccccc1Oc1nc(Nc2ccc(CO)cc2)ncc1Br

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 4/20 0.56
▸ PRKAA2 P54646 1/20 0.56
▸ PRKAA1 Q13131 1/20 0.56
▸ ULK2 Q8IYT8 1/20 0.56
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ PTK2 Q05397 5/20 0.43
▸ EGFR P00533 3/20 0.43
▸ CDK1 P06493 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ MAPK8 P45983 1/20 0.42
▸ GSK3B P49841 1/20 0.41
▸ P2RX3 P56373 1/20 0.41
▸ CHEK1 O14757 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26506579 0.89 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506589 0.89 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506580 0.88 ULK1 (0.58) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506551 0.88 ULK1 (0.61) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506558 0.86 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506572 0.86 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506586 0.86 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506588 0.85 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506584 0.84 ULK1 (0.60) ULK1PRKAA2PRKAA1ULK2KMT2A
SCHEMBL26506543 0.84 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 ULK1 2/4885PRKAA2 130/4885PRKAA1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback